Elotuzumab (Intravenous)

This is an injection used alongside other drugs to treat multiple myeloma which is a blood cell cancer.

Elotuzumab is also known under US brand name Empliciti and is used to treat a form of cancer known as multiple myeloma in patients who have received previous treatments. This medication is given into a vein.

Overview

Elotuzumab injection is used in combination with other medications to treat a blood cell cancer known as multiple myeloma in those patients who have received prior treatments. It works by interfering with the growth of cancer cells, which are then destroyed by the body itself. This medication can only be given under the supervision of a trained medical professional, typically in a clinical setting. It is available in the dosage form of powder for solution.

Condition(s) treated?

  • Multiple myeloma

Type of medicine?

  • Powder for solution

Side effects

Along with the intended effects of elotuzumab, this drug could produce some unwanted side effects. Not all of these side effects may appear, however, if they do, they may require medical attention. Inform your doctor immediately if you suffer from any of the following side effects whilst taking elotuzumab.

More common side effects

  • Vomiting or nausea

Less common side effects

  • Shiny skin bump

Some side effects that can occur with this drug usually don't require medical attention, you usually find these side effects begin to subside once your body begins to adjust to the medication. If they are bothersome, you should contact your local pharmacist or healthcare professional for advice on ways to reduce or prevent these side effects. Check with a doctor or your healthcare professional if the following effects continue or if you have any questions about them.

More common side effects

  • Muscle aches

Not all side effects are listed below and you may suffer from others. If you notice anything unusual, you should seek advice from a doctor or healthcare professional.

Remember you can report all side effects to the FDA at 1-800-FDA-1088.

Dosage

The final dose of any medication will depend on a variety of different factors that include your weight age and height. The medications you are currently taking and the severity of your condition will also be considered. Your dose may be adjusted based on your reaction to the first dose.

This medication is given in cycles. The length of a cycle is 28 days. It is given alongside dexamethasone and lenalidomide. You should also refer to the lenalidomide and dexamethasone prescribing information for more information. The typical dose for adults is:

10 mg/kg IV every week for the first two cycles and every two weeks thereafter until unacceptable toxicity levels or disease progression. Your final dose will be individualized to your response to the treatment.

Interactions

Drug interactions can cause severe side effects and reduce the effectiveness of either drug. To help limit these side effects, you should make your doctor or healthcare professional aware of all the drugs you are currently taking. This list needs to include all prescription and non-prescription drugs, vitamins and herbal remedies. You should also let your doctor know of any other medical conditions you may suffer from or any medical conditions that run in the family.

There are over 200 drugs that interact with elotuzumab. Make your doctor or healthcare professional aware if you are currently or have taken any of the following drugs listed below. The use of these drugs in combination is not usually recommended and your doctor may alter the dose or frequency in which you take either drug. In some cases, they may avoid treating you with this drug altogether.

  • Interferon beta-1b

Other interactions

If you suffer from other medical conditions, they could affect the function of this medication. Let your doctor know if you have any other medical conditions, especially:

  • Infection The use of this drug may decrease your body's ability to fight infections effectively.

Warnings

Use in pediatric population

Studies have not been conducted on the relationship of age to the effects of elotuzumab injection in the younger population. Therefore efficacy and safety have not been established so caution should be exercised.

Use in geriatric population

Studies conducted to date have not demonstrated a geriatric-specific problem that could limit the usefulness of elotuzumab injection in the older population.

Use in pregnancy and breastfeeding

Do not use elotuzumab with lenalidomide if you are pregnant. This can cause death to the infant. You will be required to use different forms of birth control to prevent pregnancy before, during, and shortly after being treated with these medications. You may need to prove a negative pregnancy test before you can start chemotherapy with this treatment and routinely every month while using this drug. Inform your doctor immediately if you fall pregnant if either the mother or the father is using elotuzumab with lenalidomide.

There are currently no studies in women that determine infant risk when using this medicine during breastfeeding. You should discuss with your doctor about the potential benefits of the potential risks before choosing to breastfeed while using this medication.

Storage

The vials should be stored intact at 36°F to 46°F (2°C to 8°C). They should be protected from light. Do not shake product or let product freeze. Infusion must be completed within a 24 period of lyophilized powder reconstitution.

Summary

When used correctly, elotuzumab is successful in assisting the treatment of multiple myeloma. The safety of this drug has not been established in children. This drug cannot be used when pregnant. Avoid falling pregnant and inform your doctor immediately if you fall pregnant before or during taking this medication. Due to a large number of interactions possible, it's vital you let your doctor know about all the current medications you are taking. This drug will be given in a hospital via injection in your arm. The dose will be adjusted to suit your individual response level.